Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents.
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.
Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.
The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.
Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights.
Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos.
A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith.
This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.
Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.
A reticent patent office and complex legal picture make getting IP protection of treatments based on the lucrative plant tricky, explain Priscila Kashiwabara and Luan Scalzitti of Kasznar Leonardos.